Literature DB >> 21493628

Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.

Santiago Vernia1, Miguel Heredia, Olga Criado, Santiago Rodriguez de Cordoba, Pablo M Garcia-Roves, Céline Cansell, Raphael Denis, Serge Luquet, Fabienne Foufelle, Pascal Ferre, Pascual Sanz.   

Abstract

Laforin is a dual specificity protein phosphatase involved in Lafora disease (LD), a fatal form of progressive myoclonus epilepsy characterized by neurodegeneration and the presence of intracellular polyglucosan inclusions (Lafora bodies) in different tissues. In this work, we describe that mice lacking laforin (epm2a-/-) have enhanced insulin response leading to altered whole-body energy balance. This enhanced insulin response overactivates the Akt pathway which increases glucose uptake in the heart, resulting in increased glycogen levels and the formation of polyglucosan inclusions. In addition, enhanced insulin response resulted in increased liver lipid biosynthesis, resulting in hepatic steatosis. On the contrary, overexpression in rat hepatoma FTO2B cells of native laforin but not of a form lacking phosphatase activity (C266S) resulted in attenuation of insulin signaling. These results define laforin as a new regulator of insulin sensitivity, which provides novel insights into LD pathogenesis and identifies this phosphatase as a potential novel component of the insulin signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493628     DOI: 10.1093/hmg/ddr157

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.

Authors:  Pankaj Kumar Singh; Sweta Singh; Subramaniam Ganesh
Journal:  Mol Cell Biol       Date:  2011-11-28       Impact factor: 4.272

Review 2.  Glycogen and its metabolism: some new developments and old themes.

Authors:  Peter J Roach; Anna A Depaoli-Roach; Thomas D Hurley; Vincent S Tagliabracci
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

Review 3.  Lafora disease offers a unique window into neuronal glycogen metabolism.

Authors:  Matthew S Gentry; Joan J Guinovart; Berge A Minassian; Peter J Roach; Jose M Serratosa
Journal:  J Biol Chem       Date:  2018-02-26       Impact factor: 5.157

4.  Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.

Authors:  Anna A DePaoli-Roach; Dyann M Segvich; Catalina M Meyer; Yasmeen Rahimi; Carolyn A Worby; Matthew S Gentry; Peter J Roach
Journal:  Hum Mol Genet       Date:  2011-12-20       Impact factor: 6.150

5.  Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.

Authors:  Yan Liu; Li Zeng; Keli Ma; Otto Baba; Pen Zheng; Yang Liu; Yin Wang
Journal:  Mol Neurobiol       Date:  2013-09-26       Impact factor: 5.590

6.  Accurate and sensitive quantitation of glucose and glucose phosphates derived from storage carbohydrates by mass spectrometry.

Authors:  Lyndsay E A Young; Corey O Brizzee; Jessica K A Macedo; Robert D Murphy; Christopher J Contreras; Anna A DePaoli-Roach; Peter J Roach; Matthew S Gentry; Ramon C Sun
Journal:  Carbohydr Polym       Date:  2019-11-20       Impact factor: 9.381

7.  WGCNA-Based DNA Methylation Profiling Analysis on Allopurinol-Induced Severe Cutaneous Adverse Reactions: A DNA Methylation Signature for Predisposing Drug Hypersensitivity.

Authors:  Lin Cheng; Bao Sun; Yan Xiong; Lei Hu; Lichen Gao; Ji Li; Hongfu Xie; Xiaoping Chen; Wei Zhang; Hong-Hao Zhou
Journal:  J Pers Med       Date:  2022-03-24

8.  Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.

Authors:  Daniel F Burgos; Lorena Cussó; Gentzane Sánchez-Elexpuru; Daniel Calle; Max Bautista Perpinyà; Manuel Desco; José M Serratosa; Marina P Sánchez
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.